A method for measuring mitochondrial DNA copy number in pediatric populations.

- 1 Simran Maggo¹, Liam Y. North², Aime Ozuna², Dejerianne Ostrow¹, Grajeda I Yander¹,
- Hakimjavadi Hesmedin¹, Jennifer A. Cotter^{1,3}, Alexander R. Judkins^{1,3}, Pat Levitt^{2,3}, *Xiaowu
 Gai^{1,3}
- Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los
 Angeles, CA
- 6 2. The Saban Research Institute, Children's Hospital Los Angeles, Los Angeles, CA
- 7 3. Keck School of Medicine, University of Southern California, Los Angeles, CA
- 8 * Correspondence:
- 9 Xiaowu Gai
- 10 xgai@chla.usc.edu

11 Keywords: Mitochondria DNA Copy Number, Adversity, lpWGS (Min.5-Max. 8)

12 Abstract

13 The mitochondrion is a multifunctional organelle that modulates multiple systems critical for 14 homeostasis during pathophysiological stress. Variation in mitochondrial DNA (mtDNA) copy 15 number (mtDNAcn), a key mitochondrial change associated with chronic stress, is an emerging 16 biomarker for disease pathology and progression. mtDNAcn can be quantified from whole blood 17 samples using qPCR to determine the ratio of nuclear DNA to mtDNA. However, the collection of 18 blood samples in pediatric populations, particularly in infants and young children, can be technically 19 challenging, yield much smaller volume samples, and can be distressing for the patients and their 20 caregivers. Therefore, we have validated a mtDNAcn assay utilizing DNA from simple buccal swabs 21 (Isohelix SK-2S) and report here it's performance in specimens from infants (age = <12 months). 22 Utilizing qPCR to amplify ~200bp regions from two mitochondrial (ND1, ND6) and two nuclear 23 (BECN1, NEB) genes, we demonstrated absolute (100%) concordance with results from low-pass 24 whole genome sequencing (lpWGS). We believe that this method overcomes key obstacles to

- 25 measuring mtDNAcn in pediatric populations and creates the possibility for development of clinical
- 26 assays to measure mitochondrial change during pathophysiological stress.

28 1 Introduction

29 The mitochondrion is an essential organelle producing cellular energy through oxidative metabolism.

30 In addition to being the "powerhouse" of the cell, mitochondria are increasingly recognized for their

31 roles in a broad range of cellular processes. Damage-associated molecular patterns (DAMPs) are

32 pathophysiological changes that occur on the cellular level that can be mediated by the release of

33 mitochondrial DNA and mitochondrial double stranded RNA into the cytoplasm during mitophagy

34 (1, 2). This may lead to increased oxidative stress and changes in nuclear gene expression, triggering

35 inflammation-related signaling pathways and systemic inflammatory responses (3-5).

36 One of the most well-studied associations between mtDNAcn and pathology is in cancer (6).

37 Increased mtDNAcn has been observed in various cancer types, including breast, lung, and colorectal

38 cancer. Known as mitochondrial biogenesis, this is thought to support the high energy demands of

39 rapidly dividing cancer cells, but may also contribute to chemoresistance, making it a potential

40 therapeutic target (7-9). Diseases may also be characterized by a reduced mtDNAcn. Mitochondrial

41 diseases often involve mutations in nuclear or mitochondrial genes that disrupt mtDNA maintenance

42 affecting energy production and causing a wide range of symptoms, such as muscle weakness,

43 neurological deficits, and organ dysfunction (1, 10, 11). Other diseases associated with changes in

44 mtDNAcn include neurodegenerative and cardiovascular diseases, and metabolic disorders including

45 type 2 diabetes and obesity (12-14).

Chronic stress, a persistent state of emotional and psychological strain, has been closely linked with changes in mtDNAcn and altered mitochondrial functioning in pre-clinical models of early adversity and in human adults (15-17). Disordered mitochondrial function may be an important contributor to the molecular mechanisms of human disease, including several mental and physical health conditions. In chronic stress, dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and increased cortisol can affect mitochondrial function and mtDNAcn (18, 19). These changes highlight the need for a reliable means of assessing mtDNAcn.

A variety of methods have been described to quantify mtDNAcn, beginning with use of a
combination of restriction enzymes and southern blotting to evaluate the intensity of nuclear to

55 mitochondrial DNA probes (20). Molecular methods including PCR, qPCR, digital PCR and

56 genomic methods including whole exome sequencing (WES) and whole genome sequencing (WGS)

57 have all been used to establish a relative mtDNAcn value by comparing nuclear to mitochondrial

- 58 intensity, CT values, copies, number of reads, respectively (3, 21, 22). PCR based approaches are
- 59 broadly cost effective for implementation of routine clinical testing. While WES/WGS are becoming
- 60 more cost-effective and are used in some specialized settings, they remain impractical for routine
- 61 clinical testing of mtDNAcn. However, given the small size of the mitochondrial genome, low pass
- 62 whole genome sequencing (lpWGS) at a read depth of 0.5 3x provides ~50X mitochondrial genome
- 63 coverage. This is sufficient for quantifying mtDNAcn and is significantly less expensive than
- 64 standard WES/WGS in settings with the capacity for clinical genomic testing (23).
- 65 To obtain sufficient volume and quality of DNA for mtDNAcn testing, conventional methods utilize
- 66 venipuncture, from which up to 10mLs of whole blood is collected (24). However, this exceeds the
- 67 recommended volume limits for infants and children (25), and venipuncture can be technically
- 68 challenging and can generate anxiety and discomfort in pediatric populations (26-28). Therefore, we
- 69 utilized buccal swabs (Isohelix SK-2S buccal swab kit and BuccalFix buffer BFX25 to stabilize DNA
- and RNA) for specimen collection as it was minimally invasive, simple to administer and cost
- 71 effective. Using DNA extracted from these swabs, we developed a mtDNAcn qPCR assay and
- 72 evaluated its performance in comparison to a commercially available mtDNAcn qPCR kit
- 73 (NovaQUANT Human Mitochondrial to Nuclear DNA ratio kit, Millipore Sigma, USA) and lpWGS.
- 74

75 2 Materials and Methods

76 2.1 Participants and study design

77 Buccal swab samples collected through Children's Hospital Los Angeles as part of the California 78 Initiative to Advance Precision Medicine (CIAPM) - Adverse Childhood Experiences (ACEs) 79 program (Scalable Measurement and Clinical Deployment of Mitochondrial Biomarkers of Toxic 80 Stress – IRB# CHLA-21-00174) and the Your Baby: Healthy Development and Resiliency (IRB# 81 CHLA-18-00547) studies were used for assay development. Participants' or their legal 82 representatives provided written consent to take part in the aforementioned studies. The ACEs study 83 samples used in this study were from 164 mothers and their infants recruited to participate at the 6-84 month timepoint of this ongoing study that also includes a 12-month infant visit. The Your Baby 85 study samples used in this study were from 19 mothers and 21 infants. A total of six samples 86 collected as part of the CIAPM study were used to validate the commercial (samples a1-a3) and our 87 own (samples b1-b3) qPCR based mtDNAcn assay. The commercial assay and lpWGS were 88 performed on 40 samples (Your Baby study, 19 mothers and their 21 infants) to assess the 89 concordance of these two techniques. However, further use of the commercial qPCR mtDNAcn 90 assay was precluded by supply chain issues which limited the availability of kits (at the time of 91 manuscript submission, the NovaQUANT assay is currently described as "limited availability" from 92 Millipore Sigma). Therefore, we established the concordance of our assay (developed with CIAPM 93 samples b1-b3) using three samples from the Your Baby study that were previously used for the 94 commercial assay and lpWGS. We then performed our mtDNAcn qPCR assay on 164 mother and 95 164 infant ACEs study samples and, finally assessed concordance using lpWGS on a subset of 36 96 samples (18 mothers and their 18 infants) from the ACEs study. The workflows and study samples 97 are summarized in Figure 1.

98 2.2 Specimen collection, DNA isolation and extraction

99 The IsoHelix SK-2S kit in combination with the BFX-25 stabilizing buffer can be used for the 100 isolation of both DNA and RNA from a single buccal swab. Caregivers were instructed not to give 101 infants food or milk for 60 minutes prior to specimen collection. Mothers utilized a gentle 'bear hug 102 technique' to hold the infant while a member of the research staff swabbed the buccal mucosa of each 103 cheek for 30 seconds (total of 60 seconds, timed), and then placed the swab into the collection tube. 104 Maternal buccal swabs were self-collected during the same visit following an identical procedure. 105 While some infants tolerated a shorter period of time (30-45 seconds), we found that moderate

106 pressure applied during swabbing for any time between 30-60 seconds is the most important element

107 for sufficient sample collection. No mother-infant pairs were excluded from the study due to

108 inadequate swab times. Collection tubes received a 500 µL aliquot of BuccalFix buffer (BFX-25)

109 and were inverted 10 times before being barcoded and stored at -80°C in the CHLA Pediatric

110 Research Biorepository. DNA and RNA were extracted using the Maxwell RSC Blood DNA kit

111 &RSC miRNA from Tissue and Plasma Kit (Promega) and stored at 4°C and -80°C, respectively,

112 until required. DNA/RNA quality (nanodrop) and quantity (Qubit) was assessed prior to use.

113 2.3 mtDNAcn assays and lpWGS

114 NovaQUANT (Millpore Sigma, USA) is a qPCR assay that assesses relative mtDNAcn by 115 comparing the ratio of mitochondrial to nuclear DNA using the Ct (Δ Ct) levels of two mitochondrial 116 genes (ND1 and ND6) and two nuclear genes (BECN1 and NEB). Real-time PCR of 4 targets (2 117 mitochondrial, 2 nuclear) was performed following the manufacturer's protocol. All samples were 118 run in triplicate (DNA - 2ng/replicate), including nuclease-free water as a no template control 119 (NTC). For analysis, we used the manufacturer's recommended method in which relative mtDNAcn 120 was calculated by assessing the ratio of mtDNA/nDNA for the MT-ND1 and MT-ND4, by the 121 geometric mean of BECN1 and NEB1.

122 Due to supply chain issues that limited availability of the commercial assay, we designed a 123 mtDNAcn qPCR assay utilizing prior published primers and mitochondrial gene target normalization 124 against nuclear genes (29) (Table1). The Ct (Δ Ct) levels of two mitochondrial genes (ND1 and ND6) 125 and two nuclear genes (BECN1 and NEB) were assessed for each DNA sample. A reference DNA-126 sample (NA12878) which has been broadly used in validating many genomic assays was included in 127 all runs. Real-time PCR of the four target genes was performed on DNA obtained from the buccal 128 swab specimens using the following cycling parameters: 95°C for 10 minutes; 40 cycles of 95°C for 129 15 seconds, 60°C for 60 seconds on the StepOnePlus[™] Real-Time PCR System (Applied 130 Biosystems, USA) and using RT² SYBR Green ROX FAST Master mix (Qiagen, USA) consisting of 131 HotStart DNA tag polymerase, nucleotides, ROX as the reference dye, and SYBR Green dye. All 132 samples were run in triplicate (DNA – 2ng/replicate), including nuclease-free water as a no template 133 control (NTC). Once normalized, the mitochondrial gene target Ct value was analyzed using the 2-134 Delta-Delta method (30) to convert the Ct value to a linear form for analysis of gene expression and 135 calculate the relative change in mitochondrial copy number. Briefly, Cts from the ND1 gene are

- 136 subtracted from that of the BECN1 gene to obtain $\Delta Ct1$ ($\Delta Ct1 = Ct^{Nuc1}-Ct^{Mito1}$), while ND6 Ct is
- 137 subtracted from NEB Ct to obtain $\Delta Ct2$ ($\Delta Ct2 = Ct^{Nuc2}-Ct^{Mito2}$), then copy numbers are calculated
- 138 based on the Δ Ct of the matched mitochondrial to nuclear DNA Cts (N = 2^{Δ Ct}). The average of the
- 139 two copy number results provides the final relative mtDNAcn per sample.
- 140 We performed lpWGS to evaluate the performance of both the commercial and our own mtDNAcn
- 141 assay (Figure 1). DNA (5ng) obtained from a subset of the same buccal swab specimens was used to
- 142 prepare NGS libraries using xGen[™] cfDNA & FFPE DNA Library Prep (Integrated DNA
- 143 Technologies Coralville, IA). NGS libraries were barcoded, pooled and sequenced on Illumina
- 144 NextSeq 500 at 2x100bp to an average read-depth ranging from 0.5 1X. Relative mtDNAcn was
- 145 then calculated using the formula mtDNAcn= (Average mitochondrial genome coverage/Average
- 146 autosomal chromosome coverage)*2, as previously described (31).
- 147 Figure 1 here.
- 148 We assessed the performance of our mtDNAcn assay by three-way comparison to the commercial
- assay and lpWGS results obtained from three samples using DNA (2ng/replicate) obtained from a
- 150 subset of the same buccal swab specimens from the Your Baby study. We were only able to perform
- this 3-way comparison on this subset of samples due to (1) limited amounts of DNA remaining and
- 152 (2) limited quantities of the commercial assay.
- 153 Table 1 here.

154 **2.4 Data analysis**

- 155 Correlation analysis and graphing were done using GraphPad Prism (version 9.5.1) and R (version
- 156 4.3.1) running in RStudio. Data are presented as means with error bars depicting standard deviation
- 157 (SD) unless otherwise specified.

158 **3 Results**

159 **3.1** Commercial assay validation and assessment

160 We initially assessed buccal swab specimens from the Your Baby study comprised of 19 mothers and 161 21 infants. As shown in Figure 2, the IsoHelix SK-2S kit in combination with the BFX-25 stabilizing 162 buffer produced high-quality DNA and RNA as assessed by 260/280 and 260/230 ratios. The 163 collection method yielded a range of 20-2000ng DNA across infant samples, and 200-4000ng DNA 164 across maternal samples (Figure 2C). We were able to elute an average of 600ng of DNA and RNA 165 in a 25uL volume, providing sufficient nucleic acid concentrations for multiple assays on each 166 sample (new Figures 2C and 2D). Prior to assessing mtDNAcn in the Your Baby study samples, we 167 conducted an inter and intra-day assay validation of the commercial NovaQUANT mtDNA qPCR 168 assay utilizing DNA obtained from three specimens (a1, a2 and a3). Inter-day variability was 169 determined by running a1, a2 and a3 in triplicate on consecutive days; intra-day variability was 170 determined by running the same samples in triplicate a second time on the same plate. 171 (Supplementary Figures s1 – s3). 172

174

We then used the commercial assay to determine mtDNAcn for Your Baby study samples utilizing
DNA available for 19 mothers and 21 infants. Our results shown in Figure 3A illustrate the mean

177 mtDNAcn level was higher in infants (229.2 \pm 66.4 S.D) than maternal samples (136.7 \pm 41.8 S.D)

178 (Figure 3A). The Your Baby samples showed a 97% concordance (Figure 3B) between the

179 commercial mtDNAcn qPCR assay and lpWGS results.

- 180
- 181 Figure 3 here.

182 **3.2** Validation and performance characterization of our qPCR assay.

183 We developed our own custom mtDNAcn qPCR assay combining methods from the commercial

assay and published primers as previously described. We performed inter- and intra-day validation

185 for our assay as described previously (**Supplementary Figures s4 -s6**). Using three samples from

¹⁷³ Figure 2 here.

186 the Your Baby Study, we performed a three-way comparison of our assay, the commercial assay and

187 lpWGS assay, and showed a 100% concordance (Pearson r of 1) for all three assays (**Figure 4**).

188 Figure 4 here.

189

190 Our own assay then was utilized to evaluate DNA from 164 mothers and 164 six-month old infant

samples collected for the ACEs study. Figure 5 shows DNA quality, quantity and mtDNAcn from

192 this cohort. In addition, we showed a high concordance between our assay and lpWGS on a subset of

193 36 ACEs samples (Pearson r = 0.94).

194 Figure 5 here.

195 **3.3 Mitochondrial haplogroup assessment**

Mitochondrial haplogroups are defined by a set of variants in the mitochondrial genome that form specific branches of the mitochondrial phylogenetic tree (32, 33). These may be useful as markers of genetic ancestry, population migrations and environmental adaptation, and certain haplogroups have been associated with susceptibility or resistance to specific diseases (34, 35). We used the Phy-mer tool that we previously developed (33) to evaluate the mitochondrial haplogroups and determine haplogroup regions for 18 mothers for which we had lpWGS data (Figure 6). The majority of maternal haplogroups were from the "Americas" region (North and South America).

203 Figure 6 here.

205 4 Discussion

206 We report the development and validation of mtDNA copy number assays that provide highly 207 reliable and reproducible results from an oral biospecimen. Using the IsoHelix SK-2S buccal swab 208 kit we were able to isolate DNA and RNA of sufficient quality and quantity from infants and adults 209 to perform qPCR based mtDNAcn and lpWGS assays from a single sample. This makes these assays 210 particularly useful for infants and young children for whom specimen collection and sample 211 limitations may effectively preclude existing methods. Our own qPCR assay required as little as 2ng 212 of DNA per qPCR replicate and our lpWGS required 5ng for library preparation. We demonstrated 213 high concordance of results from our qPCR mtDNAcn assay, a commercial qPCR mtDNAcn assay, 214 and lpWGS.

215 Different methods of measuring mtDNAcn have been evaluated previously (21). One study used data 216 from two adult cohorts, the Atherosclerosis Risk in Communities (ARIC) study and the Multi-Ethnic 217 Study of Atherosclerosis (MESA), and evaluated mtDNAcn calculated from qPCR, two microarray 218 platforms, whole genome sequencing (WGS), and whole exome sequencing (WES) (21). The results 219 showed that mtDNAcn calculated from WGS data had the strongest associations with known 220 mtDNAcn correlates, such as age, sex, white blood cell count, and incident cardiovascular disease. 221 mtDNAcn calculated from WGS also was more significantly associated with these traits compared to 222 all other methods, including qPCR. While the current study only evaluated one DNA extraction 223 method, the ARIC study also examined the impact of DNA extraction methods on mtDNAcn 224 estimation and found that measuring mtDNAcn from cell lysate resulted in less variability compared 225 to traditional methods using phenol-chloroform-isoamyl alcohol and silica-based column selection 226 (21).

227 There is growing evidence that mitochondrial adaptation as part of the cell danger response (36, 37) 228 may play a central role in various pathophysiological states, including cancer, cardiovascular disease, 229 metabolic disorders and chronic stress (16, 19, 38-43). Mitochondrial DNA copy number is a critical 230 determinant of mitochondrial function, influencing cellular energy production and metabolism (3). 231 Developing mtDNAcn assays that can be used in infants and young children provides the opportunity 232 to study whether atypical mtDNAcn may be an indicator of early pathophysiological changes that are 233 currently challenging to identify using other measures. Use of buccal swabs for sample collection and 234 a qPCR based method make our assay potentially cost effective and scalable, two key features for 235 any clinical test. While this test has broad potential application, we are particularly interested in its

- 236 utility for measuring mtDNAcn changes in infants and young children to better understand whether
- and how mtDNAcn may reflect developmental disruption due to early adversity. This requires study
- 238 of larger populations which hopefully can be more readily accomplished using this assay.

240 **5 References**

241 1. Grochowska J, Czerwinska J, Borowski LS, Szczesny RJ. Mitochondrial RNA, a new trigger of the innate 242 immune system. Wiley Interdiscip Rev RNA. 2022;13(3):e1690. 243 Qiu Y, Huang Y, Chen M, Yang Y, Li X, Zhang W. Mitochondrial DNA in NLRP3 inflammasome 2. 244 activation. Int Immunopharmacol. 2022;108:108719. 245 Filograna R, Mennuni M, Alsina D, Larsson NG. Mitochondrial DNA copy number in human disease: 3. 246 the more the better? FEBS Lett. 2021;595(8):976-1002. 247 Picard M, Wallace DC, Burelle Y. The rise of mitochondria in medicine. Mitochondrion. 2016;30:105-4. 248 16. 249 5. Wallace DC. Mitochondria as chi. Genetics. 2008;179(2):727-35. 250 Wallace DC. Mitochondria and cancer: Warburg addressed. Cold Spring Harb Symp Quant Biol. 6. 251 2005;70:363-74. 252 7. Audano M, Pedretti S, Ligorio S, Crestani M, Caruso D, De Fabiani E, et al. "The Loss of Golden 253 Touch": Mitochondria-Organelle Interactions, Metabolism, and Cancer. Cells. 2020;9(11). 254 Kaneva K, Merkurjev D, Ostrow D, Ryutov A, Triska P, Stachelek K, et al. Detection of mitochondrial 8. 255 DNA variants at low level heteroplasmy in pediatric CNS and extra-CNS solid tumors with three different 256 enrichment methods. 2021:14. 257 Kopinski PK, Singh LN, Zhang S, Lott MT, Wallace DC. Mitochondrial DNA variation and cancer. Nat 9. 258 Rev Cancer. 2021;21(7):431-45. 259 Breda CNS, Davanzo GG, Basso PJ, Saraiva Câmara NO, Moraes-Vieira PMM. Mitochondria as central 10. 260 hub of the immune system. Redox Biol. 2019;26:101255. 261 Petruzzella V, Sardanelli AM, Scacco S, Panelli D, Papa F, Trentadue R, et al. Dysfunction of 11. 262 mitochondrial respiratory chain complex I in neurological disorders: genetics and pathogenetic mechanisms. 263 Adv Exp Med Biol. 2012;942:371-84. 264 12. Kong C, Song W, Fu T. Systemic inflammatory response syndrome is triggered by mitochondrial 265 damage (Review). Mol Med Rep. 2022;25(4). 266 Norat P, Soldozy S, Sokolowski JD, Gorick CM, Kumar JS, Chae Y, et al. Mitochondrial dysfunction in 13. 267 neurological disorders: Exploring mitochondrial transplantation. NPJ Regen Med. 2020;5(1):22. 268 Pyle A, Anugrha H, Kurzawa-Akanbi M, Yarnall A, Burn D, Hudson G. Reduced mitochondrial DNA 14. 269 copy number is a biomarker of Parkinson's disease. Neurobiol Aging. 2016;38:216.e7-.e10. 270 15. Eagleson KL, Villaneuva M, Southern RM, Levitt P. Proteomic and mitochondrial adaptations to early-271 life stress are distinct in juveniles and adults. Neurobiol Stress. 2020;13:100251. 272 16. Picard M, McEwen BS. Psychological Stress and Mitochondria: A Conceptual Framework. Psychosom 273 Med. 2018;80(2):126-40. 274 17. Tyrka AR, Parade SH, Price LH, Kao HT, Porton B, Philip NS, et al. Alterations of Mitochondrial DNA 275 Copy Number and Telomere Length With Early Adversity and Psychopathology. Biol Psychiatry. 276 2016;79(2):78-86. 277 18. Lapp HE, Ahmed S, Moore CL, Hunter RG. Toxic stress history and hypothalamic-pituitary-adrenal axis 278 function in a social stress task: Genetic and epigenetic factors. Neurotoxicol Teratol. 2019;71:41-9. 279 19. Zitkovsky EK, Daniels TE, Tyrka AR. Mitochondria and early-life adversity. Mitochondrion. 280 2021;57:213-21. 281 20. Memon AA, Zoller B, Hedelius A, Wang X, Stenman E, Sundquist J, et al. Quantification of 282 mitochondrial DNA copy number in suspected cancer patients by a well optimized ddPCR method. Biomol 283 Detect Quantif. 2017;13:32-9. 284 21. Longchamps RJ, Castellani CA, Yang SY, Newcomb CE, Sumpter JA, Lane J, et al. Evaluation of 285 mitochondrial DNA copy number estimation techniques. PLoS One. 2020;15(1):e0228166. 286 22. Picard M. Blood mitochondrial DNA copy number: What are we counting? 2021:11. 287 Dong Z, Zhang J, Hu P, Chen H, Xu J, Tian Q, et al. Low-pass whole-genome sequencing in clinical 23. 288 cytogenetics: a validated approach. Genet Med. 2016;18(9):940-8.

289 24. Gillio-Meina C, Cepinskas G, Cecchini EL, Fraser DD. Translational research in pediatrics II: blood 290 collection, processing, shipping, and storage. Pediatrics. 2013;131(4):754-66. 291 Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health 25. 292 Organ. 2011;89(1):46-53. 293 Cohen LL. Behavioral approaches to anxiety and pain management for pediatric venous access. 26. 294 Pediatrics. 2008;122 Suppl 3:S134-9. 295 27. Kennedy RM, Luhmann J, Zempsky WT. Clinical implications of unmanaged needle-insertion pain and 296 distress in children. Pediatrics. 2008;122 Suppl 3:S130-3. 297 28. Meyer A, Paroni F, Gunther K, Dharmadhikari G, Ahrens W, Kelm S, et al. Evaluation of Existing 298 Methods for Human Blood mRNA Isolation and Analysis for Large Studies. PLoS One. 2016;11(8):e0161778. 299 29. Finlin BS, Memetimin H, Confides AL, Kasza I, Zhu B, Vekaria HJ, et al. Human adipose beiging in 300 response to cold and mirabegron. JCI Insight. 2018;3(15). 301 30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR 302 and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-8. 303 31. Qian Y, Butler TJ, Opsahl-Ong K, Giroux NS, Sidore C, Nagaraja R, et al. fastMitoCalc: an ultra-fast 304 program to estimate mitochondrial DNA copy number from whole-genome sequences. Bioinformatics. 305 2017;33(9):1399-401. 306 32. Kaneva K, Schurr TG, Tatarinova TV, Buckley J, Merkurjev D, Triska P, et al. Mitochondrial DNA 307 haplogroup, genetic ancestry, and susceptibility to Ewing sarcoma. Mitochondrion. 2022;67:6-14. 308 33. Navarro-Gomez D, Leipzig J, Shen L, Lott M, Stassen AP, Wallace DC, et al. Phy-Mer: a novel 309 alignment-free and reference-independent mitochondrial haplogroup classifier. Bioinformatics. 310 2015;31(8):1310-2. 311 34. Alwehaidah MS, Bakhiet M, AlFadhli S. Mitochondrial Haplogroup Reveals the Genetic Basis of 312 Diabetes Mellitus Type 2 Comorbidity in Psoriasis. Med Princ Pract. 2021;30(1):62-8. 313 35. Canter JA, Haas DW, Kallianpur AR, Ritchie MD, Robbins GK, Shafer RW, et al. The mitochondrial 314 pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral 315 neuropathy. Pharmacogenomics J. 2008;8(1):71-7. 316 Naviaux RK. Metabolic features and regulation of the healing cycle-A new model for chronic disease 36. 317 pathogenesis and treatment. Mitochondrion. 2019;46:278-97. 318 37. Naviaux RK. Metabolic features of the cell danger response. Mitochondrion. 2014;16:7-17. 319 38. Trumpff C, Michelson J, Lagranha CJ, Taleon V, Karan KR, Sturm G, et al. Stress and circulating cell-320 free mitochondrial DNA: A systematic review of human studies, physiological considerations, and technical 321 recommendations. Mitochondrion. 2021;59:225-45. 322 Trumpff C, Marsland AL, Basualto-Alarcon C, Martin JL, Carroll JE, Sturm G, et al. Acute psychological 39. 323 stress increases serum circulating cell-free mitochondrial DNA. Psychoneuroendocrinology. 2019;106:268-76. 324 40. Sharma P, Sampath H. Mitochondrial DNA Integrity: Role in Health and Disease. Cells. 2019;8(2):21. 325 41. Daniels TE, Olsen EM, Tyrka AR. Stress and Psychiatric Disorders: The Role of Mitochondria. Annu Rev 326 Clin Psychol. 2020;16:165-86. 327 42. Chaudhari PR, Singla A, Vaidya VA. Early Adversity and Accelerated Brain Aging: A Mini-Review. Front 328 Mol Neurosci. 2022;15:822917. 329 43. Hoffmann A, Spengler D. The Mitochondrion as Potential Interface in Early-Life Stress Brain 330 Programming. Front Behav Neurosci. 2018;12:306.

331

333 **5.1 Tables**

334 **Table 1 Primers utilized.**

Primer Name	Forward	Tm	Primer Name	Reverse	Tm
NEB-Fin-F1	GGCACCTCTTGATATGCTCC	58.11	NEB-Fin-R1	TATGCCTTCTTGGCAAGGTCC	60.34
BECN1-Fin-F1	GAAGTTTTCCGGCGGCTAC	62	BECN1-Fin- R1	CCGTCACCCAAGTCCGGT	64.4
ND1-Fin-F1	CCAACCTCCTACTCCTCATTGT	59.21	ND1-Fin-R1	AGGGTTGTAGTAGCCCGTAG	59.21
ND6-Fin-F1	ACTACAGCGATGGCTATTGAGG	60.7	ND6-Fin-R1	ATACTCTTTCACCCACAGCACC	60.4

335

336 6 Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial
relationships that could be construed as a potential conflict of interest.

339 7 Author Contributions

340 Simran Maggo and Dejerianne Ostrow led the development of the qPCR assays. Simran Maggo

341 drafted the original manuscript including data analysis and production of tables and figures. Liam

North and Aime Ozuna led the recruitment of study participants for the ACEs study. Yander Grajeda

343 conducted all laboratory procedures to generate all data in this manuscript. Hesmedin Hakimjavadi

- 344 assisted with lpWGS analysis. Jennifer Cotter, Alexander Judkins, Pat Levitt and Xiaowu Gai
- developed the ACEs study. Pat Levitt developed the Your Baby study. All authors contributed to
- 346 editing and final proof-reading of this manuscript.

347 8 Funding

- 348 This research project was supported by the California Initiative to Advance Precision Medicine –
- 349 ACES Program (OPR20139) and The JPB Research Network on Toxic Stress: A project of the
- 350 Center on the Developing Child at Harvard University.

351 9 Acknowledgments

- 352 This research project was supported by the California Initiative to Advance Precision Medicine –
- 353 ACES Program (OPR20139), The Saban Research Institute Developmental Neuroscience and
- 354 Neurogenetics Program, the Simms/Mann Family Foundation and the CHLA Center for Personalized
- 355 Medicine. We are grateful to Drs. Alma Gharib and Sahana Nagabhushan Kalburgi for guidance in
- 356 establishing the full research protocol and to Suchi Patel for assisting with initial data generation for
- 357 the NovaQUANT assay.
- 358
- 359

Data Availability Statement

- The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.



Compare our assay to previously

validated commercial assay

Limited quantities of DNA (Your Baby

Evaluated concordance of 3 Your Baby

samples on commercial assay, our assay

and IpWGS
 Showed 100% concordance across ALL 3

methods

study) and commercial kit.

ACEs study samples Assay deployed on ACEs cohort (164 mothers and their 164 infants)

Re-assessed 36 ACEs (18 mothers and 18 infants) using IpWGS

> 94% concordance of mtDNAcn between qPCR (our assay) and

lpWGS assay



368 **Figure 1** Study Design for qPCR mtDNA assay validation and development. (A) Commercial,

369 NovaQUANT (Millipore Sigma, USA) mtDNAcn qPCR assay validation and study samples utilized;

370 (B) our mtDNAcn qPCR assay development, validation and study samples utilized.

Assess validated assay on 40 Your Baby study samples

Ready to deploy validated commercial qPCR on ACEs study

samples, but encountered supply chain issues.

*Commercial assay supplied with human control DNA.

40 samples assessed

(19 mothers and their 21 infants)

Re-assessed using IpWGS

Showed a 97% concordance of

mtDNAcn between commercial qPCR and IpWGS

Your Baby study

40 Samples







- 374 (panels C and D) of the IsoHelix SK-2S kit in combination with the BFX-25 stabilizing buffer on 19 mother and
- 375 21 infant samples from the Your Baby study.



377 Figure 3 mtDNAcn results for commercial assay and concordance with lpWGS. Mother and

378 infant mtDNAcn assessment using the commercial assay (panel A). Strong (Pearson r= 0.97)

379 concordance of the commercial qPCR assay and lpWGS for mtDNAcn assessment (panel B).



Figure 4. Concordance of mtDNAcn between commercial, lpWGS and our own assays. *High*

- 383 (100%) concordance, **depicted as Pearson's r values**, of all three methodologies used to assess
- 384 mtDNAcn.



- 386 Figure 5. ACEs study: Nucleic acid collection results and mtDNAcn results from our qPCR and lpWGS assays.
- 387 DNA quality (Panel A), DNA quantity (Panel B), average mtDNAcn in mothers (164) and infants (164) assessed
- 388 using our qPCR assay (panel C), and concordance of 36 samples re-assessed for mtDNAcn using lpWGS (panel
- 389 D), depicted as Pearson's r values. RNA quality and quantity was also assessed and is shown in
- 390 Supplementary Figure s7.
- 391





Figure 6. Mitochondrial haplogroups determination. *Evaluation of mitochondrial haplogroups for 18*

394 maternal samples that underwent *lpWGS* showed most falling into North America/South America, with small

- 395 numbers from other haplogroup regions.

398 11 Supplementary Material

399 11.1 Inter and intra-day validation of the commercial NovaQUANT mtDNA qPCR assay





Figure s1. Mitochondrial DNA copy number assay validation. The qPCR assay utilizes two nuclear (NEB, BECN1) and two mitochodnrial genes (ND1, ND6). The graphs above show the average CT values \pm SD from three separate validation runs. In each run the individual DNA sample was run in triplicate. Positive control (PC) is a DNA sample provided by the kit manufacturer.



Figure s2. Panel A - DNA samples were assayed in 3 separate validation runs (R1, R2, R3). R1 and R2 are inter-day validation runs. R3 is the intra-day validation run. In the third validation run (R3,intra-day), each sample was run twice (in triplicate). Panel B - Average of all runs. The graphs above show the average mitochondrial DNA copy number ± SD.



Figure s3. The graphs above show validation results from intra (A) and inter (B) runs. Inter-day results show relative mitochondrial DNA copy number \pm SD from samples run consecutively on two separate days on different plates in triplicate. Intra-day results show relative mitochondrial DNA copy number \pm SD from samples run TWICE on the same plate in triplicate.

404 11.2 Inter- and intra-day validation of our qPCR mtDNAcn assay



Intra-Day Validation (in-house qPCR mtDNAcn assay)

Figure s4 shows results of INTRA-day validation of in-house qPCR mtDNAcn assay. Run2 (R2) was carried out in the morning, and RUN3 (R3) was carried out in the afternoon of the same day. The different colored bars represent samples b1, b2, b3 and internal standard DNA sample - NA12878 respectively.

405

406

Inter-Day validation (In-house qPCR mtDNAcn assay).



Figure s5 shows INTER-DAY validation of in-house qPCRmtDNA assay. Run1 (R1) and Run2 (R2) were carried out on consecutive days. Run 2 and Run3 (R3) were carried out on the same day. The different colored bars represent samples b1, b2, b3 and internal standard DNA sample - NA12878 respectively.

407



Average mtDNAcn variation (in-house assay validation)

Figure s6 shows the average mtDNAcn and standard deviations from three separate runs.

11.3 RNA quality and quantity of extracted RNA from ACEs study



411 Figure s7 RNA quality (panels A) and quantity (Panel B) of 164 mother and 164 infant samples from
412 the ACEs cohort.